Foresite Capital Portfolio
13F Holdings & Position Changes — Last filed May 15, 2026
13F Holdings & Position Changes — Last filed May 15, 2026
Foresite Capital is a $4B biotech-focused hedge fund managed by Jim Tananbaum, MD. As of their latest 13F filing (Q1 2026), the fund holds 8 positions worth $237.1M. This quarter they initiated 1 new position and exited 7. Their largest holding is PHVS ($135.0M).
Foresite initiated 1 new position and increased 2 this quarter. Portfolio grew +15.6% to $237.1M. 33 upcoming catalysts across holdings.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
Foresite Capital held 8 biotech stocks in their 13F portfolio this quarter. Their top positions include PHVS, CYTK, EIKN, LYEL, RLAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Foresite Capital's tracked biotech portfolio is worth $237.1M across 8 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
Foresite Capital initiated 1 new position this quarter, including EIKN. They also increased 2 existing positions.
Foresite Capital fully exited 7 positions this quarter, including CBAY, NTRA, QSIAW, ACRS, SNDX and 2 more. They also trimmed 1 existing positions.
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.